Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

The development of neutralizing antibodies can limit the therapeutic effectiveness of systemically administered oncolytic viruses (OV). Here, to enable repeated intravenous administration, the authors report the development of synthetic RNA viruses formulated within lipid nanoparticles, showing anti...

Full description

Bibliographic Details
Main Authors: Edward M. Kennedy, Agnieszka Denslow, Jacqueline Hewett, Lingxin Kong, Ana De Almeida, Jeffrey D. Bryant, Jennifer S. Lee, Judy Jacques, Sonia Feau, Melissa Hayes, Elizabeth L. McMichael, Daniel Wambua, Terry Farkaly, Amal A Rahmeh, Lauren Herschelman, Danielle Douglas, Jacob Spinale, Sanmit Adhikari, Jessica Deterling, Matt Scott, Brian B. Haines, Mitchell H. Finer, Ted T Ashburn, Christophe Quéva, Lorena Lerner
Format: Article
Language:English
Published: Nature Portfolio 2022-10-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-022-33599-w

Internet

https://doi.org/10.1038/s41467-022-33599-w

Similar Items